The therapeutic potential of dopamine modulators on the cardiovascular and renal systems

Expert Opinion on Investigational Drugs

Volumn 11, Issue 5, 2002, Pages 631-644

  Doggrell, Sheila A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Docarpamine; Dopamine; Fenoldopam; Glu dopa; Ibopamine; Nitecapone

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 (3,4 DIHYDROXYPHENYL) 1,2,3,4 TETRAHYDRO 7,8 DIHYDROXYISOQUINOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; [(S) 6 [[6 [[2 (2 METHOXYPHENOXY)ETHYL]AMINO] HEXYL] PROPYLAMINO] 5,6,7,8 TETRAHYDRO 1,2 NAPHTALENEDIOL DIHYDROCHLORIDE; ANTIARRHYTHMIC AGENT; BUMETANIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCARPAMINE; DOMPERIDONE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FENOLDOPAM; FUROSEMIDE; GAMMA GLUTAMYLDOPA; IBOPAMINE; INOTROPIC AGENT; LEVODOPA; NITECAPONE; NITROPRUSSIDE SODIUM; PRODRUG; SULPIRIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; Z 1046;

ACUTE HEART FAILURE; AGING; ASCITES; CARDIOGENIC SHOCK; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DIURESIS; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FORWARD HEART FAILURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE; LIVER CIRRHOSIS; MORTALITY; NATRIURESIS; NAUSEA; NONHUMAN; PATHOGENESIS; PERIPHERAL CIRCULATION; REVIEW; URINARY TRACT; VASCULAR RESISTANCE; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASCULARIZATION;

AGING; ANIMAL; CARDIOVASCULAR SYSTEM; DOPAMINE; DOPAMINE AGONISTS; HUMAN; HYPERTENSION; KIDNEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RENAL CIRCULATION; ANIMALS; HUMANS;

EID: 0035999739     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.5.631     Document Type: Review

References (96)

1. 2-like receptors in the rat kidney: Effect of denervation
2. Renal response to amino acid infusion in rats: Effect of dopamine receptor antagonists and benserazide
3. Dopamine D2 receptors mediate glomerular hyperfiltration due to amino acids
4. 2-loke receptors and amino acid-induced glomerular hyperfiltration in humans
5. Postglomerular vasoconstriction induced by dopamine D3 receptor activation in anesthetized rats
6. Intrarenal dopamine: A key signal in the interactive regulation of sodium metabolism
7. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule
8. Dopamine D4 receptor isoform mRNA and protein are expressed in the rat cortical collecting duct
9. Renal dopamine system
10. 1A receptor induces antinatriuresis in conscious rats
11. +-ATP-ase is associated with endocytosis of its α- and β-subunits
12. +-Pi cotransport in opossum kidney cells
13. Dopamine regulates phosphate uptake by opossum kidney cells through multiple counter-regulatory receptors
14. Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects
15. A study on the renal synthesis of dopamine in aged rats
16. A decreased tubular uptake of dopa results in defective renal dopamine production in aged rats
17. 1 receptor and G proteins in renal proximal tubules of old rats
18. +-ATPase activity is lacking in Dahl salt-sensitive rats
19. 3 receptors and salt-dependent hypertension
20. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease
21. 1A dopamine receptor in the pathogenesis of genetic hypertension
22. Type 1a dopamine receptor expression in the heart is not altered in spontaneously hypertensive rats
23. Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice
24. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension
25. 1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats
26. Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat
27. (q/11) proteins in spontaneously hypertensive rats
28. 2-like receptors in the kidney of spontaneously hypertensive rats: A radioligand binding assay and light microscopic autoradiography study
29. Plasma and urinary catecholamines in salt-sensitive idiopathic hypertension
30. Deficiency of renal dopaminergic-dependent natriuretic response to acute sodium load in black salt-sensitive subjects in contrast to salt-resistant subjects
31. Abnormal distal tubular sodium reabsorption during dopamine infusion in patients with essential hypertension evaluated by the lithium clearance methods
32. Differential human renal tubular responses to dopamine Type 1 receptor stimulation are determined by blood pressure status
33. Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension
34. Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation
35. Two distinct promoters drive transcription of the human D1A dopamine receptor gene
36. Detection of four polymorphic sites in the human dopamine D1 receptor gene (DRD1)
37. Dopamine D1 receptor gene polymorphism is associated with essential hypertension
38. Defective dopamine generation from dihydoxyphenylalanine in stable essential hypertensive patients
39. 1-like receptor signal transduction in obese hypertensive rats
40. Decreased urinary dopamine excretion and disturbed dopamine/sodium relationship in Type I diabetes mellitus
41. Dopamine-sodium relationship in Type 2 diabetic patients
42. 2-like receptor blockade in experimental diabetes mellitus
43. Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction
44. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy
45. Renal dose dopamine does not alter the response to β-adrenergic stimulation by isoproterenol in healthy human volunteers
46. Dopamine natriuresis in salt-repleted, water-loaded humans: A dose-response study
47. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: Safety and cost efficacy
48. Use of dopamine in acute renal failure: A meta-analysis
49. The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: Does it protect renal function?
50. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial
51. Low-dose dopamine in neonatal and pediatric intensive care: A systematic review
52. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography
53. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency
54. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation
55. Effects of low-dose dopamine on urine output in oliguric, critically ill, renal transplant patients
56. Low-dose dopamine after kidney transplantation: Assessment by Doppler ultrasound
57. Renal effects of L-DOPA in heart failure
58. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TS-870) in humans
59. A novel, orally active dopamine prodrug TA-870. V. Natriuretic and positive inotropic effects in rats: An assessment after chronic administration
60. The effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats
61. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery
62. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: A pilot study
63. +-ATPase
64. Patients with essential hypertension have an exaggerated natriuretic response to the dopamine pro-drug glutamyl-dopa
65. Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin-induced diabetes in rats
66. +-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate
67. Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin and on renal function
68. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats
69. 1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors
70. Effect of ibopamine on diuresis in conscious rats in normal and experimentally altered conditions
71. Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: Comparison with epinine and dopamine
72. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog
73. Low-dosage ibopamine treatment in progressive renal failure: A long-term multicentre trial
74. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure
75. Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy
76. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure
77. Comparison of captopril and ibopamine in mild to moderate heart failure
78. Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure
79. Clinical efficacy of ibopamine in patients with chronic heart failure
80. Randomised study of ibopamine on survival in patients with advanced severe heart failure
81. Risk factors for mortality in users of ibopamine
82. Direct vasodilating effects of the new dopaminergic agonist Z-1046 in human arteries
83. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z-1046
84. Fenoldopam: Renal and splanchnic effects in patients undergoing coronary artery bypass grafting
85. Fenoldopam, a dopamine agonist for hypertensive emergency: A multicenter randomized trial
86. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors
87. Effects of fenoldopam on systemic and splanchnic haemodynamics and oxygen delivery/consumption relationship during hyperdynamic ovine endotoxaemia
88. Identification of fenoldopam prodrugs with prolonged vasodilator activity
89. Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058
90. 1-receptor agonist, in anaesthetized dogs
91. 1 receptor agonist, in a canine model of ischemic acute renal failure
92. Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure
93. Xamoterol in severe heart failure
94. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
95. Effect of oral milrinone on mortality in severe chronic heart failure
96. Treatment of severe heart failure: Quantity or quality of life? A trial of enoximone